Arkolith/Insider Trading/EYEP/Form 4

Ocumension Therapeutics

DirectorEyePoint Pharmaceuticals, Inc. (EYEP) · full profile →Form 4 · filed Dec 7, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$19.5M
Net Open-Market Flow
-$19.5M
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 6, 2023Sell(S)266K$18.41$4.9M2.0M
Dec 5, 2023Sell(S)734K$19.91$14.6M2.3M

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001840315-23-000007) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML